TQ-F3083 / Centaurus Biopharma - LARVOL DELTA

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults. (PubMed, Front Pharmacol) - "The concentration of active glucagon-like peptide-1 increased after TQ-F3083 administration, but no obvious dose dependency was observed. TQ-F3083 was well tolerated in healthy Chinese adults, and the pharmacokinetic and pharmacodynamic characteristics support further evaluation of TQ-F3083 in a trial in T2DM patients."

Clinical • Journal • P1 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P2a; N=120; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jul 2019 ➔ Jan 2020

Clinical • Enrollment open • Trial initiation date